ArticleNeuropathology and applied neurobiology2013
Nuclear carrier and RNA-binding proteins in frontotemporal lobar degeneration associated with fused in sarcoma (FUS) pathological changes.
Abstract read
In one paragraph
Article in Neuropathology and applied neurobiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 34 citations in OpenAlex.
- TAF15 amyloids propagate via defined motifs in a prion-like fashion.Nature communications · 2026Article
- RNA-binding proteins in ALS and FTD: from pathogenic mechanisms to therapeutic insights.Molecular neurodegeneration · 2025Review
- Nuclear-import receptors as gatekeepers of pathological phase transitions in ALS/FTD.Molecular neurodegeneration · 2024Review
- Article
- Article
- Fused in Sarcoma Neuropathology in Neurodegenerative Disease.Cold Spring Harbor perspectives in medicine · 2017Review
- Frontotemporal lobar degeneration: Pathogenesis, pathology and pathways to phenotype.Brain pathology (Zurich, Switzerland) · 2017Review
- Heterogeneous ribonuclear protein A3 (hnRNP A3) is present in dipeptide repeat protein containing inclusions in Frontotemporal Lobar Degeneration and Motor Neurone disease associated with expansions in C9orf72 gene.Acta neuropathologica communications · 2017Article
- Role of FET proteins in neurodegenerative disorders.RNA biology · 2016Review
- FUS is phosphorylated by DNA-PK and accumulates in the cytoplasm after DNA damage.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2014Article
- Arginine methylation next to the PY-NLS modulates Transportin binding and nuclear import of FUS.The EMBO journal · 2012Article
- Mechanisms of disease in frontotemporal lobar degeneration: gain of function versus loss of function effects.Acta neuropathologica · 2012Review
- The RNA-binding protein FUS is chaperoned and imported into the nucleus by a network of import receptors.The Journal of biological chemistryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 7 institutions in 2 countries.
Y S DavidsonMental Health and Neurodegeneration Research Group, Faculty of Human and Medical Sciences, University of Manchester, ManchesterCerebral Function Unit, Greater Manchester Neuroscience Centre, Salford Royal Foundation Trust, SalfordDepartment of Neuropathology, Walton Centre for Neurology and Neurosurgery, LiverpoolNeuropathology/Cellular Pathology, Royal Victoria InfirmaryInstitute for Ageing and Health, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UKNorthwestern CNADC Neuropathology Core, Northwestern University Feinberg School of Medicine, Chicago, Illinois, Departments ofNeurologyPathology & Immunology, Washington University School of Medicine, St Louis, Missouri, USA.
A C RobinsonMental Health and Neurodegeneration Research Group, Faculty of Human and Medical Sciences, University of Manchester, ManchesterCerebral Function Unit, Greater Manchester Neuroscience Centre, Salford Royal Foundation Trust, SalfordDepartment of Neuropathology, Walton Centre for Neurology and Neurosurgery, LiverpoolNeuropathology/Cellular Pathology, Royal Victoria InfirmaryInstitute for Ageing and Health, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UKNorthwestern CNADC Neuropathology Core, Northwestern University Feinberg School of Medicine, Chicago, Illinois, Departments ofNeurologyPathology & Immunology, Washington University School of Medicine, St Louis, Missouri, USA.
Q HuMental Health and Neurodegeneration Research Group, Faculty of Human and Medical Sciences, University of Manchester, ManchesterCerebral Function Unit, Greater Manchester Neuroscience Centre, Salford Royal Foundation Trust, SalfordDepartment of Neuropathology, Walton Centre for Neurology and Neurosurgery, LiverpoolNeuropathology/Cellular Pathology, Royal Victoria InfirmaryInstitute for Ageing and Health, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UKNorthwestern CNADC Neuropathology Core, Northwestern University Feinberg School of Medicine, Chicago, Illinois, Departments ofNeurologyPathology & Immunology, Washington University School of Medicine, St Louis, Missouri, USA.
M MishraMental Health and Neurodegeneration Research Group, Faculty of Human and Medical Sciences, University of Manchester, ManchesterCerebral Function Unit, Greater Manchester Neuroscience Centre, Salford Royal Foundation Trust, SalfordDepartment of Neuropathology, Walton Centre for Neurology and Neurosurgery, LiverpoolNeuropathology/Cellular Pathology, Royal Victoria InfirmaryInstitute for Ageing and Health, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UKNorthwestern CNADC Neuropathology Core, Northwestern University Feinberg School of Medicine, Chicago, Illinois, Departments ofNeurologyPathology & Immunology, Washington University School of Medicine, St Louis, Missouri, USA.
A BaborieMental Health and Neurodegeneration Research Group, Faculty of Human and Medical Sciences, University of Manchester, ManchesterCerebral Function Unit, Greater Manchester Neuroscience Centre, Salford Royal Foundation Trust, SalfordDepartment of Neuropathology, Walton Centre for Neurology and Neurosurgery, LiverpoolNeuropathology/Cellular Pathology, Royal Victoria InfirmaryInstitute for Ageing and Health, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UKNorthwestern CNADC Neuropathology Core, Northwestern University Feinberg School of Medicine, Chicago, Illinois, Departments ofNeurologyPathology & Immunology, Washington University School of Medicine, St Louis, Missouri, USA.
E JarosMental Health and Neurodegeneration Research Group, Faculty of Human and Medical Sciences, University of Manchester, ManchesterCerebral Function Unit, Greater Manchester Neuroscience Centre, Salford Royal Foundation Trust, SalfordDepartment of Neuropathology, Walton Centre for Neurology and Neurosurgery, LiverpoolNeuropathology/Cellular Pathology, Royal Victoria InfirmaryInstitute for Ageing and Health, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UKNorthwestern CNADC Neuropathology Core, Northwestern University Feinberg School of Medicine, Chicago, Illinois, Departments ofNeurologyPathology & Immunology, Washington University School of Medicine, St Louis, Missouri, USA.
R H PerryMental Health and Neurodegeneration Research Group, Faculty of Human and Medical Sciences, University of Manchester, ManchesterCerebral Function Unit, Greater Manchester Neuroscience Centre, Salford Royal Foundation Trust, SalfordDepartment of Neuropathology, Walton Centre for Neurology and Neurosurgery, LiverpoolNeuropathology/Cellular Pathology, Royal Victoria InfirmaryInstitute for Ageing and Health, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UKNorthwestern CNADC Neuropathology Core, Northwestern University Feinberg School of Medicine, Chicago, Illinois, Departments ofNeurologyPathology & Immunology, Washington University School of Medicine, St Louis, Missouri, USA.
N J CairnsMental Health and Neurodegeneration Research Group, Faculty of Human and Medical Sciences, University of Manchester, ManchesterCerebral Function Unit, Greater Manchester Neuroscience Centre, Salford Royal Foundation Trust, SalfordDepartment of Neuropathology, Walton Centre for Neurology and Neurosurgery, LiverpoolNeuropathology/Cellular Pathology, Royal Victoria InfirmaryInstitute for Ageing and Health, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UKNorthwestern CNADC Neuropathology Core, Northwestern University Feinberg School of Medicine, Chicago, Illinois, Departments ofNeurologyPathology & Immunology, Washington University School of Medicine, St Louis, Missouri, USA.
A RichardsonMental Health and Neurodegeneration Research Group, Faculty of Human and Medical Sciences, University of Manchester, ManchesterCerebral Function Unit, Greater Manchester Neuroscience Centre, Salford Royal Foundation Trust, SalfordDepartment of Neuropathology, Walton Centre for Neurology and Neurosurgery, LiverpoolNeuropathology/Cellular Pathology, Royal Victoria InfirmaryInstitute for Ageing and Health, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UKNorthwestern CNADC Neuropathology Core, Northwestern University Feinberg School of Medicine, Chicago, Illinois, Departments ofNeurologyPathology & Immunology, Washington University School of Medicine, St Louis, Missouri, USA.
A GerhardMental Health and Neurodegeneration Research Group, Faculty of Human and Medical Sciences, University of Manchester, ManchesterCerebral Function Unit, Greater Manchester Neuroscience Centre, Salford Royal Foundation Trust, SalfordDepartment of Neuropathology, Walton Centre for Neurology and Neurosurgery, LiverpoolNeuropathology/Cellular Pathology, Royal Victoria InfirmaryInstitute for Ageing and Health, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UKNorthwestern CNADC Neuropathology Core, Northwestern University Feinberg School of Medicine, Chicago, Illinois, Departments ofNeurologyPathology & Immunology, Washington University School of Medicine, St Louis, Missouri, USA.
D NearyMental Health and Neurodegeneration Research Group, Faculty of Human and Medical Sciences, University of Manchester, ManchesterCerebral Function Unit, Greater Manchester Neuroscience Centre, Salford Royal Foundation Trust, SalfordDepartment of Neuropathology, Walton Centre for Neurology and Neurosurgery, LiverpoolNeuropathology/Cellular Pathology, Royal Victoria InfirmaryInstitute for Ageing and Health, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UKNorthwestern CNADC Neuropathology Core, Northwestern University Feinberg School of Medicine, Chicago, Illinois, Departments ofNeurologyPathology & Immunology, Washington University School of Medicine, St Louis, Missouri, USA.
J S SnowdenMental Health and Neurodegeneration Research Group, Faculty of Human and Medical Sciences, University of Manchester, ManchesterCerebral Function Unit, Greater Manchester Neuroscience Centre, Salford Royal Foundation Trust, SalfordDepartment of Neuropathology, Walton Centre for Neurology and Neurosurgery, LiverpoolNeuropathology/Cellular Pathology, Royal Victoria InfirmaryInstitute for Ageing and Health, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UKNorthwestern CNADC Neuropathology Core, Northwestern University Feinberg School of Medicine, Chicago, Illinois, Departments ofNeurologyPathology & Immunology, Washington University School of Medicine, St Louis, Missouri, USA.
E H BigioMental Health and Neurodegeneration Research Group, Faculty of Human and Medical Sciences, University of Manchester, ManchesterCerebral Function Unit, Greater Manchester Neuroscience Centre, Salford Royal Foundation Trust, SalfordDepartment of Neuropathology, Walton Centre for Neurology and Neurosurgery, LiverpoolNeuropathology/Cellular Pathology, Royal Victoria InfirmaryInstitute for Ageing and Health, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UKNorthwestern CNADC Neuropathology Core, Northwestern University Feinberg School of Medicine, Chicago, Illinois, Departments ofNeurologyPathology & Immunology, Washington University School of Medicine, St Louis, Missouri, USA.
D M A MannMental Health and Neurodegeneration Research Group, Faculty of Human and Medical Sciences, University of Manchester, ManchesterCerebral Function Unit, Greater Manchester Neuroscience Centre, Salford Royal Foundation Trust, SalfordDepartment of Neuropathology, Walton Centre for Neurology and Neurosurgery, LiverpoolNeuropathology/Cellular Pathology, Royal Victoria InfirmaryInstitute for Ageing and Health, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UKNorthwestern CNADC Neuropathology Core, Northwestern University Feinberg School of Medicine, Chicago, Illinois, Departments ofNeurologyPathology & Immunology, Washington University School of Medicine, St Louis, Missouri, USA.
Salford Royal NHS Foundation Trust · GBUniversity of Manchester · GBNorthwestern University · USNewcastle Hospitals - Campus for Ageing and Vitality · GBNewcastle University · GBWalton Centre · GBWashington University in St. Louis · US
Funding
Smartphone-Based "Burst" Cognitive AssessmentsP01AG003991 · NIA · WASHINGTON UNIVERSITY · PI Tammie Lee Smith Benzinger · 1985 to 2026
$69.5MWASHINGTON UNIVERSITY ALZHEIMERS DISEASE RESEARCH CENTERP50AG005681 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 1985 to 2019
$52.1MNeuropathology CoreP30AG013854 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BIGIO, EILEEN H. · 1996 to 2020
$28.9MMedical Research Council G0400074Medical Research Council G0502157Medical Research Council G0900652Medical Research Council G1100540NIA NIH HHS AG13854NIA NIH HHS P01 AG003991NIA NIH HHS P01 AG03991NIA NIH HHS P30 AG013854NIA NIH HHS P50 AG005681NIA NIH HHS P50 AG05681Wellcome Trust 089701
Abstract
aimsWe aimed to investigate the role of the nuclear carrier and binding proteins, transportin 1 (TRN1) and transportin 2 (TRN2), TATA-binding protein-associated factor 15 (TAF15) and Ewing's sarcoma protein (EWS) in inclusion body formation in cases of frontotemporal lobar degeneration (FTLD) associated with fused in sarcoma protein (FTLD-FUS).
methodsEight cases of FTLD-FUS (five cases of atypical FTLD-U, two of neuronal intermediate filament inclusion body disease and one of basophilic inclusion body disease) were immunostained for FUS, TRN1, TRN2, TAF15 and EWS. Ten cases of FTLD associated with TDP-43 inclusions served as reference cases.
resultsThe inclusion bodies in FTLD-FUS contained TRN1 and TAF15 and, to a lesser extent, EWS, but not TRN2. The patterns of immunostaining for TRN1 and TAF15 were very similar to that of FUS. None of these proteins was associated with tau or TDP-43 aggregations in FTLD.
conclusionsData suggest that FUS, TRN1 and TAF15 may participate in a functional pathway in an interdependent way, and imply that the function of TDP-43 may not necessarily be in parallel with, or complementary to, that of FUS, despite each protein sharing many similar structural elements.
Indexed as
Adultbeta KaryopherinsDNA-Binding ProteinsFemaleFrontotemporal Lobar DegenerationHumansInclusion BodiesMaleMiddle AgedRNA-Binding Protein EWSRNA-Binding Protein FUSTATA-Binding Protein Associated Factorsbeta KaryopherinsDNA-Binding ProteinsFUS protein, humanRNA-Binding Protein EWSRNA-Binding Protein FUSTAF15 protein, humanTATA-Binding Protein Associated FactorsTNPO1 protein, humanTNPO2 protein, humanEwing's sarcoma proteinfrontotemporal lobar degenerationfused in sarcomaTATA-binding protein-associated factor 15TDP-43transportins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.